GKOS
Glaukos CorporationNYSEHealthcare$112.77+0.12%ClosedMarket Cap: $6.55B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
9.88
P/S
12.91
EV/EBITDA
-45.12
DCF Value
$-88.39
FCF Yield
-0.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.7%
Operating Margin
-15.4%
Net Margin
-37.0%
ROE
-25.4%
ROA
-27.4%
ROIC
-9.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $143.1M | 83.8% | $-18.4M | $-133.7M | $-2.32 | — |
| FY 2025 | $507.4M | 55.7% | $-199.6M | $-187.7M | $-3.28 | — |
| Q3 2025 | $133.5M | 78.4% | $-16.4M | $-16.2M | $-0.28 | — |
| Q2 2025 | $124.1M | 78.3% | $-22.7M | $-19.7M | $-0.34 | — |
| Q1 2025 | $106.7M | 77.2% | $-20.7M | $-18.1M | $-0.32 | — |
| Q4 2024 | $105.5M | 72.9% | $-28.7M | $-33.6M | $-0.60 | — |
| FY 2024 | $383.5M | 75.5% | $-122.4M | $-146.4M | $-2.77 | — |
| Q3 2024 | $96.7M | 76.6% | $-24.7M | $-21.4M | $-0.39 | — |
| Q2 2024 | $95.7M | 76.4% | $-30.0M | $-50.5M | $-1.06 | — |
| Q1 2024 | $85.6M | 76.3% | $-39.1M | $-40.8M | $-0.82 | — |
| Q4 2023 | $82.4M | 77.1% | $-38.6M | $-36.8M | $-0.75 | — |
| FY 2023 | $314.7M | 76.0% | $-128.7M | $-134.7M | $-2.78 | — |